12 Month Price Forecast For CRVO
Distance to CRVO Price Forecasts
CRVO Price Momentum
๐ค Considering Cervomed (CRVO)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 16, 2025 2:20 AM UTC
CRVO Analyst Ratings & Price Targets
Based on our analysis of 10 Wall Street analysts, CRVO has a neutral consensus with a median price target of $12.00 (ranging from $4.00 to $34.00). The overall analyst rating is Buy (6.3/10). Currently trading at $2.33, the median forecast implies a 415.0% upside. This outlook is supported by 2 Buy, 5 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Jason Kolbert at D. Boral Capital, projecting a 1,359.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CRVO Analyst Consensus
CRVO Price Target Range
Latest CRVO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CRVO.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Dec 17, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Downgrade | $0.00 |
Dec 11, 2024 | Chardan Capital | Daniil Gataulin | Neutral | Downgrade | $0.00 |
Dec 11, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $12.00 |
Dec 10, 2024 | D. Boral Capital | Jason Kolbert | Hold | Downgrade | $0.00 |
Dec 10, 2024 | Jones Trading | Soumit Roy | Hold | Downgrade | $0.00 |
Dec 5, 2024 | Roth MKM | Boobalan Pachaiyappan | Buy | Initiates | $45.00 |
Dec 5, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Initiates | $42.00 |
Nov 27, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $34.00 |
Nov 18, 2024 | D. Boral Capital | Jason Kolbert | Buy | Initiates | $34.00 |
Nov 14, 2024 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $55.00 |
Sep 18, 2024 | Chardan Capital | Daniil Gataulin | Buy | Initiates | $55.00 |
Jul 26, 2024 | Morgan Stanley | Jeffrey Hung | Overweight | Initiates | $35.00 |
Jul 25, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $65.00 |
Jul 8, 2024 | Brookline Capital | Tyler Bussian | Buy | Initiates | $63.00 |
May 29, 2024 | Jones Trading | Soumit Roy | Buy | Initiates | $70.00 |
Apr 8, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $65.00 |
Feb 15, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Initiates | $50.00 |
Aug 16, 2022 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Upgrade | $9.50 |
Nov 25, 2020 | H.C. Wainwright | Buy | Reiterates | $0.00 | |
Nov 17, 2020 | HC Wainwright & Co. | Neutral | Downgrade | $0.00 |
Stocks Similar to Cervomed Inc.
The following stocks are similar to Cervomed based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cervomed Inc. (CRVO) Financial Data
Cervomed Inc. has a market capitalization of $19.23M with a P/E ratio of 4.9x. The company generates $10.07M in trailing twelve-month revenue with a -118.7% profit margin.
Revenue growth is +27.1% quarter-over-quarter, while maintaining an operating margin of -278.2% and return on equity of -43.3%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Cervomed Inc. (CRVO) Company Overview
About Cervomed Inc.
Develops treatments for age-related neurologic disorders.
CervoMed Inc. focuses on developing and commercializing innovative therapeutics targeting age-related neurological conditions. The company generates revenue through the advancement of its drug candidates, such as neflamapimod, which aims to address significant unmet medical needs in dementia and related disorders.
Founded in 2010 and based in Boston, Massachusetts, CervoMed is actively engaged in preclinical trials for its EIP200 candidate, indicating a strong pipeline for future growth. The company's focus on age-related neurological disorders positions it in a growing market driven by an aging population.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
8
CEO
Dr. John J. Alam M.D.
Country
United States
IPO Year
2023
Website
www.cervomed.comCervomed Inc. (CRVO) Latest News & Analysis
CervoMed Inc. (NASDAQ: CRVO) will present topline results from its Phase 2b RewinD-LB study on neflamapimod for dementia with Lewy bodies at the ILBDC on January 31, 2025.
The presentation of Phase 2b results for CervoMed's neflamapimod at a major conference could significantly impact stock performance, influencing investor sentiment around its potential in treating DLB.
CervoMed's experimental drug for a common degenerative brain disease failed to meet primary and secondary goals in a mid-stage clinical trial, according to their announcement on Tuesday.
CervoMed's failed trial may lead to reduced investor confidence, potential stock price decline, and concerns over future drug development and funding prospects.
CervoMed Inc. (CRVO) stock declined following the release of topline data from its Phase 2b clinical trial of neflamapimod for dementia with Lewy bodies.
CervoMed's stock decline reflects investor concern over trial results for neflamapimod, potentially impacting future revenue and market confidence in the company's pipeline.
CervoMed Inc.'s stock dropped significantly after the company announced that a midstage trial for its DLB treatment did not achieve its primary objectives.
CervoMed's stock drop signals negative investor sentiment due to failed clinical trial results, raising concerns about the company's future prospects and financial health.
CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
2 months agoNeflamapimod failed to show statistically significant effects compared to placebo on primary and secondary endpoints after 16 weeks of study.
Neflamapimod's failure in clinical trials raises concerns about its market viability, potentially impacting the company's stock and investor confidence in its drug pipeline.
CervoMed Inc. (NASDAQ: CRVO) has granted equity awards to attract two new employees, indicating its commitment to expanding its team in age-related neurologic disorder treatments.
CervoMed's equity awards signal confidence in growth and potential, impacting investor sentiment and stock performance as the company expands its talent for drug development.
Frequently Asked Questions About CRVO Stock
What is Cervomed Inc.'s (CRVO) stock forecast for 2025?
Based on our analysis of 10 Wall Street analysts, Cervomed Inc. (CRVO) has a median price target of $12.00. The highest price target is $34.00 and the lowest is $4.00.
Is CRVO stock a good investment in 2025?
According to current analyst ratings, CRVO has 2 Buy ratings, 5 Hold ratings, and 1 Sell ratings. The stock is currently trading at $2.33. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for CRVO stock?
Wall Street analysts predict CRVO stock could reach $12.00 in the next 12 months. This represents a 415.0% increase from the current price of $2.33. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cervomed Inc.'s business model?
CervoMed Inc. focuses on developing and commercializing innovative therapeutics targeting age-related neurological conditions. The company generates revenue through the advancement of its drug candidates, such as neflamapimod, which aims to address significant unmet medical needs in dementia and related disorders.
What is the highest forecasted price for CRVO Cervomed Inc.?
The highest price target for CRVO is $34.00 from Jason Kolbert at D. Boral Capital, which represents a 1,359.2% increase from the current price of $2.33.
What is the lowest forecasted price for CRVO Cervomed Inc.?
The lowest price target for CRVO is $4.00 from at , which represents a 71.7% increase from the current price of $2.33.
What is the overall CRVO consensus from analysts for Cervomed Inc.?
The overall analyst consensus for CRVO is neutral. Out of 10 Wall Street analysts, 2 rate it as Buy, 5 as Hold, and 1 as Sell, with a median price target of $12.00.
How accurate are CRVO stock price projections?
Stock price projections, including those for Cervomed Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.